Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Faruk Bhagani Joins Element Blue’s Healthcare Technology Practice


Faruk’s depth of experience will greatly contribute to the continued growth of our intelligent automation practice. – Steven Gerhardt, CEO

Element Blue, a Houston-based healthcare technology consultancy and certified custom solution provider, announced that Faruk Bhagani has joined the firm as senior vice president, sales.

“We are pleased to welcome Faruk to Element Blue,” said Steven Gerhardt, Managing Partner & CEO. “His industry knowledge and experience in leading high-performing sales teams will benefit our clients and is integral to the continued growth of our intelligent automation healthcare practice.”

“I have observed and been impressed by Element Blue’s success for many years,” said Bhagani. “I look forward to contributing to its vision for the future as the healthcare sector further embraces innovative technology solutions.”

Bhagani brings more than two decades of international entrepreneurial and high-tech sales leadership and a history of generating 8-figure sales revenues to the role at Element Blue. Most recently at Salesforce, he supported enterprise professional services firms in leveraging the Salesforce portfolio to transform client digital journeys.

Active in his community both professionally and personally, Bhagani is a founding member of OPEN SoCal, a global non-profit that promotes entrepreneurial and professional development for the South Asian diaspora across professional industries. In addition, he works with Houston-area non-profits to extend and further their causes by serving as master of ceremony and host for their fundraising and community development events.

Bhagani received his master’s degree in financial strategy from Oxford University and his undergraduate degree from the University of Houston.

About Element Blue

Element Blue (http://www.elementblue.com) enables healthcare systems to transform the patient experience and reduce costs through increased personalization and intelligent automation. The practice’s Blueprint Services Framework impacts patient access, referrals, digital marketing and the revenue cycle at the most critical stages of the customer journey, resulting in a seamless encounter across the system.

By empowering patients and employees to actively manage their unique healthcare experiences, Element Blue increases the satisfaction of every health system consumer: customers, patients and members.

Houston-based, Element Blue has offices in Dubai, Hyderabad, Nairobi, Lima, Buenos Aires, and San Jose. For more information, please go to ElementBlue.com.

Share article on social media or email:

The National Infertility Association to Observe National Infertility Awareness Week®


Let’s use National Infertility Awareness Week to raise our voices, talk about the issues too many of us face, and ensure we continue supporting those most in need.

RESOLVE: The National Infertility Association will recognize National Infertility Awareness Week®, April 23 through April 29, 2023. The movement brings together millions of Americans who want to remove the stigmas and barriers that stand in the way of building families. RESOLVE will rally the infertility community to raise awareness about the significant lack of access to family building options and emotional support for millions of women and men struggling to build a family. #FindYourVoice will be a message found on the official NIAW website and throughout RESOLVE’s social media campaigns.

“Millions of people face barriers to building a family whether they are facing infertility, having trouble sustaining a pregnancy, or people in the LGBTQ+ community. The barriers include access to care, financial limitations, and even proposed legislation and policies which could make it impossible to access family building options like IVF. We encourage those who struggle to build a family to use our resources and find their voice,” said Barbara Collura, RESOLVE’s President/CEO. “Let’s use NIAW to raise our voices, talk about the issues too many of us face, and ensure we continue supporting those most in need.”

Throughout NIAW, the infertility and family building community will take to social media and share their stories in different ways through RESOLVE’s 5-Day Challenge and lead the conversation about challenges to family building and methods of resolution. Through national media, social media, and fundraising, the infertility community will take action to increase awareness of infertility to remove stigmas and improve access to family building options.

On Tuesday, April 25, in partnership with the American Society for Reproductive Medicine, RESOLVE will bring more than 400 advocates to virtual meetings with hundreds of Members of Congress. The annual Advocacy Day will focus on access to care issues like insurance coverage for IVF for federal employees, protecting access to IVF, the adoption tax credit, and removing barriers to medical treatment for our Veterans and servicemembers.

RESOLVE’s National Infertility Awareness Week 2023 is supported by the following partners: Church & Dwight Co., Inc. makers of First Response™; CooperSurgical; EMD Serono; Encompass Fertility by CVS; Ferring Pharmaceuticals; Organon; Progyny; TMRW; and US Fertility.

NIAW became a federally recognized health observance by the Department of Health and Human Services in 2010. RESOLVE can provide experts for interviews on all aspects of infertility, and personal patient stories from women and men struggling to build their families. Find out more about NIAW at infertilityawareness.org.

# # #

About RESOLVE: The National Infertility Association: Established in 1974, RESOLVE: The National Infertility Association is a non-profit organization with the only established, nationwide network mandated to promote reproductive health and to ensure equal access to all family building options for men and women experiencing infertility or other reproductive disorders. One in eight U.S. couples of childbearing age has trouble conceiving or carrying a pregnancy to term. RESOLVE addresses this public health issue by providing community to these women and men, connecting them with others who can help, empowering them to find resolution and giving voice to their demands for access to all family building options. For more information, visit http://www.RESOLVE.org.

Share article on social media or email:

Next-Generation Complement Therapeutics — Exploring Challenges and Solutions from Bench to Bedside, Upcoming Webinar Hosted by Xtalks


The rise in the number of conditions linked to dysregulation of the complement system clearly underscores the potential of complement-modulating therapeutics.

Complement is an important and integral part of the immune system known to interact with a wide range of tissues and cells across the body. However, only recently has it become an attractive therapeutic target. In this panel discussion, attendees will gain knowledge on the challenges and potentials of complement therapeutics from drug discovery all the way through to clinical testing.

The introduction of Eculizumab, the pioneering complement modulator, demonstrated that targeting the complement system is well-tolerated, provides beneficial treatment and can change, and potentially save, lives. The rise in the number of conditions linked to dysregulation of the complement system clearly underscores the potential of complement-modulating therapeutics.

However, many attempts to make new drugs have failed. This has served as a valuable lesson to scientists and researchers, highlighting the importance of understanding the complexities of the complement system and the need for specialized tools to successfully develop effective drugs.

Over the last few decades, multiple initiatives have been launched — because of both the success with Eculizumab and a better understanding of the complement system — ranging from academic laboratories to large pharmaceutical companies exploring further the potential of regulating the complement system. A considerable number of these complement therapeutics have entered clinical development, and several are even in advanced late trial stages.

Equipped with these insights and the technical advancements in biological drug design, novel complement modulating drugs are emerging to avoid previous pitfalls and thus increase the chances of clinical success. This creates a promising outlook for those aiming to leverage the potential therapeutic applications of modulating the complement system and bringing it to the clinic to improve the health of patients.

Register for this webinar to hear from experts on next-generation complement therapeutics as they provide perspectives and insights from each stage of the drug development process.

Join Dr. Michael Schwenkert, Chief Technology Officer, Svar Life Science; Dr. Christoph Schmidt, Professor of Biochemical Pharmacy, Institute of Pharmacy, Martin-Luther University of Halle-Wittenberg; Dr. Előd Körtvély, Principal Scientist, Pharma Research and Early Development (pRED), Roche Innovation Center; Dr. Sandra Wymann, Senior Manager, Translational Research, CSL Behring AG, for the live webinar on Tuesday, April 11, 2023, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Next-Generation Complement Therapeutics — Exploring Challenges and Solutions from Bench to Bedside.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Belt Technologies, Inc., introduces TruPulley line of products


This line of pulleys is a testament to our commitment to engineering excellence and innovation within the conveying system market. We know this new line will exceed customer expectations and are excited to see all the applications it will benefit.

Belt Technologies, Inc., a manufacturer of custom metal belt conveyor solutions for more than 50 years, is introducing the new TruPulleyTM line of products, which all work to monitor or regulate the tension, pace or tracking of a metal belt. The patent-pending TruTensionTM, TruPaceTM and TruTrackTM pulleys are available as standalone products or as part of a conveyor system designed by Belt Technologies engineers and manufactured in the United States.

“After years of dedication to creating these superior products, we are excited to finally release them to the world,” said Belt Technologies CEO Denis Gagnon. “This line of pulleys is a testament to our commitment to engineering excellence and innovation within the conveying system market. We know this new line will exceed customer expectations and are excited to see all the applications it will benefit.”

The TruTensionTM Pulley incorporates sensors to measure the tension of a steel belt, allowing users to optimize the belt’s performance and maximize its lifespan. The TruTensionTM pulley leverages a small, enclosed controller (separate from the pulley) that senses the bearing load in the pulley. Through a calibration process, the pulley measures the belt tension and displays it digitally on the controller display—making TruTensionTM a first of its kind in the marketplace.

The TruPaceTM Pulley consists of a thin-walled tube with end caps that add rigidity and allow for multiple mounting options for the end user. These pulleys can be accelerated very quickly with low power output and can be customized to meet customer specifications. Compared to standard pulley designs of similar diameter and width, the TruPaceTM Pulley offers a significant decrease in inertia to allow designers to specify smaller motors and gearboxes for their equipment.

The TruTrackTM Pulley precisely automates belt tracking by using a segmented roller design that moves with virtually no friction along the shaft between two edge guides, improving the lifespan of the belt. The segmented design of the TruTrackTM Pulley substantially reduces side loads on the belt, preventing damage to its edge and improving belt life in ways standard edge guides or flanges can’t.

“We are very proud of these products and the work that went into their development,” said Belt Technologies President Alan Wosky. “There are countless applications for these pulleys, and with our customization capabilities, the possibilities are endless.”

Belt’s PureSteel® products drive productivity with custom automation solutions complete with engineering support from concept to completion. Through sophisticated engineering, advanced manufacturing processes and unlimited custom designs, their products can suit any application.

About Belt Technologies

Belt Technologies, Inc., has been producing custom metal belt conveyor solutions for new and existing conveyor systems for more than five decades. Sophisticated engineering, advanced manufacturing processes, and an unlimited variety of configurations and coatings are available to custom-design belts to suit any application. Metal belts, timing belts, and metal drive tapes are superior, high-quality options for automated production and robotic facilities. A subsidiary, Belt Technologies Europe (BTE), located in Tyne and Wear in the U.K., serves as the sales office for Europe and Asia. To learn more about Belt Technologies and metal conveyor belts, visit belttechnologies.com.

Share article on social media or email:

Cardiac Imaging, ECG and the Role for Patient-Reported Outcomes, Upcoming Webinar Hosted by Xtalks


Cardio-oncology, an evolving subspecialty focused specifically on the detection and management of these risks, has become an essential consideration within any oncology development program.

As clinical research in the oncology therapeutic area becomes increasingly complex, effectively capturing high-quality data across multiple endpoints becomes even more critical to a drug’s success. Many oncologic agents have cardiac toxicities, including depression of left ventricular function, QTc prolongation and elevation of blood pressure.

Register for this webinar to learn about the intersection of oncology drug development and cardiac safety, and how this new area is changing the landscape for early-phase clinical trials.

Cardio-oncology, an evolving subspecialty focused specifically on the detection and management of these risks, has become an essential consideration within any oncology development program. Additionally, with the growing emphasis on patient-focused drug development, recent regulatory guidelines now outline core patient-reported outcomes (PROs) that should be included in oncology clinical trials.

Among these are self-reported symptomatic adverse events, with the new 2023 US Food and Drug Administration (FDA) draft guidance acknowledging the importance of utilizing this self-reported data to enhance the assessment of tolerability in early-phase dose optimization trials.

To accommodate the recommendations for enhanced detection strategies, the featured speakers will discuss key topics, including: Feasibility and best practices for PRO collection; Technologies for ECG collection; Blood pressure monitoring and cardiac imaging; And enhancing data quality without substantially increasing patient burden.

The integration of objectively measured safety endpoints with PROs is essential in characterizing the safety profile of a drug, which ultimately informs the overall benefit-risk considerations for the program.

Join this webinar for an introduction to cardio-oncology and ECG best practices, as well as a discussion of the benefits of PROs.

Join experts from Clario, Todd Rudo, MD, EVP & Chief Medical Officer; Robert Kleiman, MD, Vice President & Chief Medical Officer, Cardiology; Mori Krantz, MD, Senior Cardiologist, Chief Science Advisor, Cardiac Safety & Cardiovascular Imaging; and Kelly Dumais, PhD, Principal Scientific Advisor, for the live webinar on Tuesday, April 11, 2023, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Safety and Tolerability in Oncology Trials: Cardiac Imaging, ECG and the Role for Patient-Reported Outcomes.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Whitney Scholarship Fund will Benefit Brunswick High School Graduates


Nancy H. Whitney

The Nancy H. Whitney, R.N. Scholarship Fund has been established with The Community Foundation of Frederick County and becomes one of its more than 770 component charitable funds.

To honor their mother and her positive impact on those around her, Jana Lamonica, Amy Whitney, and Stephen Whitney have created The Nancy H. Whitney, R.N. Scholarship Fund. Nancy worked as a registered nurse at Frederick Health Hospital and was committed to whole-person health care. Her husband, Joseph, had a final wish that this fund be created in his wife’s memory so her legacy of care and dedication within the community would continue. The fund will provide financial assistance for Brunswick High School graduates, including nontraditional students, pursuing an education in the healthcare field.

As a leader in grant and scholarship funding, The Community Foundation of Frederick County has given back more than $86 million to the community since 1986.

To learn more about how the Community Foundation impacts Frederick County, visit http://www.FrederickCountyGives.org.

Share article on social media or email:

There’s No Escaping the New Hypervisual World; Men Take a Page From the Women’s Virtual Playbook


News Image

The stigma of vanity surrounding cosmetic procedures for men has evaporated. Minimally invasive treatments with little downtime and natural-looking results give men the same benefits women have enjoyed for decades — enhanced self-esteem, confidence, and sociability

Men’s approach to skincare has been historically minimalistic — soap, water, shave, repeat. Their number one grooming accessory, the razor, has evolved over the decades from one single blade to up to five and counting. Until recently, men seemingly stuck to the conventional notion that men, as opposed to women, “look better as they age.” Or, so the story goes — or went. However, civilization has become high-tech and hypervisual, and there are metaphorical mirrors everywhere — selfies, social media, videoconferencing — and it’s not always possible to hide behind an anti-aging filter. Once considered a “metrosexual” indulgence, men increasingly view aesthetic enhancements as a necessary investment to boost self-confidence and succeed in a virtual business world. Cynthia Elliott, MD, owner and primary practitioner of Skinspirations, says, “The stigma of vanity surrounding cosmetic procedures for men has evaporated. Minimally invasive treatments with little downtime and natural-looking results give men the same benefits women have enjoyed for decades — enhanced self-esteem, confidence, and sociability.”

According to a study by The American Society of Plastic Surgeons, between 2000 and 2020, for men, there has been a 137% increase in soft tissue fillers, a 182% increase in skin rejuvenating injectables, and a 482% increase in laser skin resurfacing. (1) While it’s been generally accepted that female celebrities maintain their flawless skin and youthful appearance with routine aesthetic treatments, it’s taken a bit longer for famous men to come out of the shadows regarding what the zeitgeist endearingly refers to as “Brotox.” Men are turning to aesthetic treatments to maximize their potential in all aspects of their lives.

The International Society of Aesthetic Plastic Surgery reported that male cosmetic procedures have increased by more than 325% since 1997. And one not-so-surprising motivator, aside from having a dynamic social media presence, is the proliferation of Marvel movies, with men who ooze masculinity and are the archetypal embodiment of male perfection. (2) At Skinspirations, increasingly popular male aesthetic treatments include sculpting strong and chiseled jawlines, higher cheekbones, body contouring, unwanted hair, vein & spot removal, tattoo removal or fading, hair growth, and acne scar treatments.

There is still a vestige of bias when it comes to men taking advantage of the same non-invasive and revolutionary aesthetic treatments now widely available to the general public, not just the privileged elites. For male and female celebrities, cosmetic procedure failures tend to get more attention than successes. However, male celebrity procedural misses tend to get a louder thumping on social media than their female counterparts.

Dr. Elliott emphasizes that “Experience and integrity matter. Skinspirations is a medical practice, not a spa. Our team of licensed providers is exceedingly knowledgeable and highly skilled in using the tools and medical-grade products not offered through med spas. All of us at Skinspirations have a passion for providing our patients with the most honest and knowledgeable advice possible to address their aesthetic concerns, even if it means telling them they don’t need any of our services.”

Contrary to the now-defunct Marlboro Man image of rugged masculinity, today’s men are breaking free from a singular perception of maleness toward a broader range of thinking, where men can be more open about their insecurities and take more confident steps toward improving their exterior and interior self in an increasingly meta worldview.

About Dr. Cynthia Elliott and Skinspirations

Cynthia Elliott, M.D., is the owner and primary practitioner of Skinspirations, a cosmetic and regenerative medical practice that provides injectable and laser aesthetic treatments, professional skincare, body contouring, and regenerative treatments for aesthetic and musculoskeletal concerns. Located in Clearwater, Florida, Dr. Elliott is valued for her medical expertise and her training on the national level for the makers of Botox® Cosmetic and Juvéderm and internationally for Cutera Lasers. Her patients seek her expertise, knowing that she and her long-tenured staff have trained many professionals in the Tampa Bay area. Skinspirations has performed over 88,000 cosmetic medical treatments since 2005 and is known for the most effective aesthetic and regenerative medical treatments available, providing the quality results that other practitioners are still trying to learn. Dr. Elliott, whose medical training began in emergency medicine, currently serves as an expert witness in Cosmetic Medicine for the Florida Board of Medicine.

For more information, visit http://www.skinspirations.com.

Sources:

1. Cosmetic surgery gender distribution male – American society of plastic … (n.d.). Retrieved February 21, 2023, from plasticsurgery.org/documents/News/Statistics/2020/cosmetic-procedures-men-2020.pdf

2. “Do All Men Want to Look like Superheroes, the Zoom Focus on Facial Flaws, Nose Tip Droopage, Treatments for Profuse Sweating.” Skinspirations, myemail.constantcontact.com/Do-all-men-want-to-look-like-superheroes–the-Zoom-focus-on-facial-flaws–nose-tip-droopage—-treatments-for-profuse-sweating.html?soid=1101853765215;aid=z24Ucoqna8Q.

Share article on social media or email:

ScitoVation Announces Next Generation, Non-animal Genotoxicity Program


ScitoVation - Pioneers in chemical safety assessments

Pioneers in chemical safety assessments

Our genotox program is aimed at identifying potential genotoxicity hazards early, saving time and resources by reducing the potential for positive outcomes in the regulatory genetic toxicology test battery that can stop further development

ScitoVation today announced the availability of next generation, non-animal genotoxicity assays for lead candidate selection. These assessments will provide clients genotoxicity assessments during drug discovery or early lead compound development that are highly predictive of outcomes from the regulatory genetic toxicology test battery.

Knowledge regarding the potential of pharmaceuticals, food additives or chemicals to damage the human genome and cause mutations remains critical to public health. Mutations are key events in the induction of cancer, birth defects, and neurological disease. The regulatory genetic toxicology test battery required by the US Food and Drug Administration (FDA) for Investigational New Drug applications to initiate clinical trials, and by the US Environmental Agency (EPA) for registration of pesticides, includes approved in vitro tests for assessing genotoxicity and mutagenicity. A positive response in this regulatory test battery can eliminate drug candidates from further development or require further in vivo testing to demonstrate safety, which add significant time to development and can be costly.

ScitoVation’s New Genotoxicity Program includes:

  • Computational Tools for Testing Mutagenicity (AMES Test): Quantitative structural-activity relationship (QSAR) tools that are highly predictive of bacterial mutagenicity test (Ames Test). The use of QSAR offers an efficient means from both cost and timing perspective to triage candidates and focus additional in vitro testing on more promising candidates.
  • Micronucleus Assay: For lead candidates, the OECD approved in vitro micronucleus assay using human TK6 or HepaRG™ cells.
  • Toxicogenomic Genotoxicity Biomarker TgX-DDI: provides a point of departure that can be used to translate the in vitro results to human equivalent dose. This biomarker is currently undergoing FDA validation as biomarker predictive of mammalian genotoxicity.

Current genetic toxicology assessments are increasingly challenging due to backlogs and outdated technologies. ScitoVation’s Chief Scientific Officer and program creator, Leslie Recio, PhD, explains, “Our genotox program is aimed at identifying potential genotoxicity hazards early, saving time and resources by reducing the potential for positive outcomes in the regulatory genetic toxicology test battery that can stop further development.”

Dr. Jean Orelien, ScitoVation CEO, is pleased to offer this program to clients: “I’m pleased that in addition to providing the regulatory accepted micronucleus assay, consistent with our commitment to innovate for our clients, we will provide additional value by helping our clients assess genotoxicity using promising novel methods such as toxicogenomics.”

ScitoVation is focused on modernizing safety assessment for early-stage development using human biological models integrated with mode-of-action genomic and computational toxicology tools as New Approach Methodologies (NAMs) for human risk assessments.

Ordering for the micronucleus assay will open on April 2nd. Please visit http://www.scitovation.com/genotoxicity for more information.

About ScitoVation

ScitoVation helps clients develop safer and more effective pharmaceuticals, food ingredients, agricultural chemicals, commodity chemicals, and consumer products using innovative science and next generation technology.  The company is known for partnership, flexibility, and proven success in assisting clients to address safety and effectiveness for both internal stakeholders and regulators. Recognized as industry experts in the use of New Approach Methods (NAMs), the team pioneered cell-based and computational methods to provide leading-edge solutions with results that are scientifically sound and withstand scrutiny, including from peer-reviewers and regulators.

Share article on social media or email:

Riverside Insights and Kognito Partner to Offer Intervention Professional Development for School Health Providers


Riverside Insights

The reality is that 75% of mental health conditions emerge by the age of 14, but often the evidence is misattributed as the child being apathetic or disengaged.

Riverside Insights®, a leading developer of research-based assessments and analytics, today announced a partnership with Kognito, a provider of practice-based digital learning experiences, which provides strategies to improve mental health and well-being across schools. With this collaboration, school health professionals, such as psychologists, counselors and school nurses, will have access to additional training to support mental health-related cognitive interventions for at-risk students.

Centers for Disease Control and Prevention (CDC) research shows that in 2021 more than four in 10 students felt persistently sad or hopeless and nearly one-third (29%) experienced poor mental health. Through the partnership, health professionals will have additional training to notice the early signs and establish a therapeutic collaboration with the student.

“Riverside Insights’ partnership with Kognito is another example of our commitment to supporting the whole child,” said Sunjay Talele, clinical general manager at Riverside Insights. “School health professionals play a critical role in identifying and supporting students with behavioral or mental health concerns. Together we can provide the tools and training necessary to effectively manage the specific conversation with each student to motivate healthy behaviors.”

Now, school health professionals and educators will have access to a variety of interactive trainings that are proven to lead to more impactful conversations and outcomes with students. The Kognito Learning Model includes the following key components:


  • Didactic Lessons + Interactive Conversations: Learners gain key knowledge in conversation and social and emotional learning (SEL) skills, followed by practice opportunities. This practice-based experiential learning builds the skills and confidence needed to effectively approach important conversations.
  • Real-Life Scenarios: Relatable scenarios evoke an emotional response to create a powerful experience. Content is based on the input of thousands of educators and students and reveals the cause and effect relationship between the learners’ communication strategies and the responses they elicit.
  • Virtual Coaches: Learners have access to virtual coaching in the platform, which allows for more transformative learning moments where the user can reflect on how they are doing and what steps they can take to improve. This allows for a deeper understanding of the communication strategies taught.
  • Kognito Virtual Humans: Each Kognito simulation consists of interactive didactic modules and a series of roleplay conversations. Users engage in hands-on practice leading conversations with virtual, fully animated and emotionally responsive humans. Kognito’s virtual humans are scientifically designed to embody specific personalities, attitudes, and medical/behavioral health conditions.

“The reality is that 75% of mental health conditions emerge by the age of 14, but often the evidence is misattributed as the child being apathetic or disengaged,” said Deborah Serri, vice president of Product, Kognito. “The Kognito training helps guide school health professionals, nurses, psychologists, teachers, and counselors so they can identify warning signs early. Kognito role-play simulations enable schools and districts to rapidly build the capacity of educators and students to lead real-life conversations that change lives.”

About Kognito

Kognito is a leading provider of practice-based digital learning experiences that provide strategies to improve mental health and well-being across schools, campuses, and communities. Built on an interactive platform, the products integrate several evidence-based models and techniques, game mechanics, and learning principles, allowing users to learn by engaging in role-play conversations with emotionally responsive humans. Through practice and personalized feedback, users learn and assess their competency to lead similar real-life conversations. Kognito has been instrumental in providing training to over 1.5 million educators, administrators, students, and their communities. This innovative approach is changing lives by increasing user confidence and awareness on critical topics that impact critical thinking and decision-making. For more information, visit kognito.com.

About Riverside Insights

Riverside Insights, one of the nation’s leading and most long-standing developers of research-based assessments, is led by a powerful mission: to provide insights that help elevate potential and enrich the lives of students, clinical patients, employees, and organizations globally. For more information, visit http://www.RiversideInsights.com.

Share article on social media or email:

Proscia Announces Major Expansion In Preclinical R&D To Drive Faster Drug Safety Decisions


“Expanding our solutions for preclinical R&D came in response to customer demand. We are helping them to increasingly realize the efficiency and quality gains that Concentriq for Research delivers as the place where work happens and data lives.” – Nathan Buchbinder, Proscia’s Chief Product Officer

Proscia®, a leading provider of digital and computational pathology solutions, has strengthened its position in the $12 billion[1] preclinical research and development (R&D) market. At the center of its expansion, the company is enhancing its flagship Concentriq® for Research, trusted by 14 of the top 20 pharmaceutical companies as a singular software platform for pathology workflows and data, to accelerate Good Laboratory Practice (GLP) and non-regulated drug safety studies.

Preclinical R&D, which demonstrates if a drug is safe to advance to human clinical trials, centers around workflows with higher volumes of pathology data than any other phase of drug discovery and development. Life sciences organizations are now rapidly adopting digital pathology to drive efficiency and quality gains in their routine operations, streamlining collaboration and improving the reproducibility of results.

“Digital pathology is enabling preclinical pathology and R&D teams to do their jobs better,” said Aleksandra Zuraw, Veterinary Pathologist, Digital Pathologist, and Publisher of Digital Pathology Place. “By shifting from microscope to whole slide image, scientists can work more productively and deliver more consistent results.”

Announced today, Proscia is extending the scalable, intuitive Concentriq for Research to increasingly drive preclinical R&D with new features and services including:

  • Robust capabilities for GLP compliance. Life sciences organizations can conduct GLP studies in the same platform as their non-regulated discovery and preclinical research. In addition to offering audit logs, enterprise administration, and archiving workflows on Concentriq for Research, Proscia has made available GLP validation services to help teams realize the benefits of digital pathology sooner.
  • A new Studies module that streamlines toxicopathology workflows. Concentriq for Research now enables whole slide image scoring and peer review with the introduction of a Studies module. Scientists can manage study frameworks, simultaneously collect pathologists’ assessments, and instantly evaluate results, easily capturing structured data to help improve reproducibility and drive more efficient analysis.
  • Expanded Automated Quality Control (QC) for preclinical image data. On top of improving the performance of the platform’s embedded Automated QC on images of H&E stained slides, Proscia has expanded it to also detect commonly occurring quality issues on images of immunohistochemistry (IHC) and special stained slides. Regions of interest can be shared with integrated image analysis applications to further ensure the quality of study data.

“Expanding our solutions for preclinical R&D was an obvious step for us that came in response to growing customer demand,” said Nathan Buchbinder, Proscia’s Chief Product Officer. “These life sciences organizations are making important drug safety decisions that play a key role in getting new therapies to patients. We are now helping them to increasingly realize the efficiency and quality gains that Concentriq for Research delivers as the place where work happens and data lives.”

A modern pathology platform, Concentriq for Research is used by leading pharmaceutical companies, contract research organizations (CROs), and emerging biotechs to drive their research across the R&D value chain. It serves as an enterprise-wide system of record for pathology data and sits at the center of routine operations, enabling diverse workflows, streamlining collaboration, and unlocking new insights with artificial intelligence (AI). In doing so, the platform is enabling life sciences organizations to better tap into their pathology data from discovery to development to advance the next wave of innovation.

To see a live demonstration of the expanded Concentriq for Research, visit Proscia at booth #636 during the Society of Toxicology 62nd Annual Meeting and ToxExpo. Proscia will also be showcasing the new features during a live webinar on Wednesday, May 3 at 11 AM EDT.

About Proscia

Proscia is a software company that is accelerating pathology’s digital transformation to change the way we understand diseases like cancer. Its Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate discovery, improve patient outcomes, and fulfill the promise of precision care. Leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies rely on Proscia’s software each day. For more information, visit proscia.com.

[1] Wilson, E., Willoughby, R., & Wallach, M. (2016). CRO Industry Primer. Equity Research: Life Science Tools and Diagnostics. Credit Suisse. Retrieved from https://bit.ly/3FzTBWN

Share article on social media or email: